<DOC>
	<DOCNO>NCT00531453</DOCNO>
	<brief_summary>The purpose Phase 2 randomize study evaluate efficacy safety treatment regimen VELCADE , dexamethasone , thalidomide ( VDT ) VELCADE , dexamethasone , thalidomide , cyclophosphamide ( VDTC ) subject newly diagnose symptomatic multiple myeloma receive prior treatment candidate receive high-dose therapy autologous bone marrow/stem cell transplantation .</brief_summary>
	<brief_title>A Study Evaluate Two Different Regimens VELCADE Combination With Dexamethasone , Thalidomide Cyclophosphamide ( VDT v VDTC ) Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Male female ≥18 ≤70 year Patient candidate HDT combine autologous SCT Karnofsky Performance Status score ≥60 % Multiple myeloma diagnose accord follow standard criterion AND require systemic therapy : Presence Mcomponent serum and/or urine , plus clonal plasma cell bone marrow and/or document clonal plasmacytoma PLUS 1 following : 1 . Calcium elevation ( &gt; 11.5 mg/dL &gt; 2.65 mmol/L ) 2 . Renal insufficiency ( creatinine &gt; 2 mg/dL &gt; 177 umol/L ) 3 . Anemia ( hemoglobin &lt; 10 g/dL [ &lt; 12.5 mmol/L ] least 2 mg/dL [ 1.25 mmol/L ] normal ) 4 . Bone disease ( lytic lesion osteopenia ) AND fulfill criterion measurable disease , define least 1 follow 3 measurement : 1 . Serum Mprotein ≥1 g/dL ( ≥10 g/L ) 2 . Urine Mprotein ≥200 mg/24 h 3 . Serum free light chain ( FLC ) assay : Involved FLC level ≥10 mg/dL ( ≥100 mg/L ) provide serum FLC ratio abnormal Women childbearing potential must agree use 2 method contraception . Males must agree use barrier contraception . Subjects ( legally acceptable representative ) must sign informed consent document . To participate optional pharmacogenomic component study , subject ( legally acceptable representative ) must sign informed consent form . Refusal consent component exclude subject participation clinical study . Diagnosis smolder OR nonsecretory multiple myeloma monoclonal gammopathy undetermined significance ( MGUS ) . Diagnosis Waldenström 's disease condition IgM Mprotein present absence clonal plasma cell infiltration lytic bone lesion . Prior current systemic therapy multiple myeloma include steroid . Radiation therapy and/or plasmapheresis within 15 day randomization . History allergic reaction attributable compound give ( VELCADE , thalidomide , dexamethasone , and/or cyclophosphamide ) compound contain boron mannitol . Peripheral neuropathy neuropathic pain Grade 2 high , defined National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 3.0 . Uncontrolled severe cardiovascular disease Concurrent medical condition disease ( e.g. , active systemic infection , uncontrolled diabetes ) likely interfere study procedure result , opinion investigator would constitute hazard participate study . Use investigational drug within 30 day randomization Pregnant lactate woman : A serum βhCG pregnancy test must perform Screening visit female subject childbearing potential . Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>